We are thrilled to announce the launch of Oncology Outcomes: Strategic Advisory Partnership.

“This partnership sees us dramatically expanding the scope of our oncology resources and expertise available to our clients. Through this world-class research group, we will be bringing a patient-centered focus to oncology drug development and real-world evidence generation through strategic advising.”

Stacie Hudgens, COS’s President

Pictured left to right, Stacie Hudgens and Tara Symonds.

To provide dedicated strategic advice for your oncology patient-centered evidence strategy.

Through this oncology advisory partnership, we will support you on every step of the journey: from early development to post-approval, including real world surveillance.

Our combined qualitative, quantitative, and regulatory expertise will demonstrate the value (or clinical benefit) of your product to key stakeholders (e.g. patients, providers, regulators, and reimbursement authorities).

COS has worked extensively in oncology since its start in 2013 to incorporate qualitative inquiry and advance quantitative methods in cancer research.  Stacie Hudgens has worked in the oncology COA space for the past 20 years in her industry, academic, and consultancy roles.  She has extensive publications and presentations detailing novel methodologies for analyzing and interpreting COA endpoints in clinical trials.  Alongside Tara Symonds, Louise Newton, and Claire Burbridge, she has co-led the development of real-world research methods to triangulate evidence from multiple stakeholder groups.  Stacie has participated in a number of oncology-specific working groups and continues to work to push the scientific standards for understanding treatment burden for cancer patients.